The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-01

Study Completion Date

2026-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85% of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and poor survival rate HCC is ranked as the sixth most common type of cancer and the third leading cause of cancer-related mortalities world wide.

HCC incidences arise in complications associated with chronic liver disease like cirrhosis, endemic hepatitis B virus (HBV)/hepatitis C virus (HCV) infections, non alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (Torre, 2015).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Accuracy of APAC, ASAP and GALAD Scores in Hepatocellular Carcinoma Among Cirrhotic Patients

NCT05738772

Hepatocellular Carcinoma

UNKNOWN

Serum Visfatin and Serum Vaspin in Patients With Hepatocellular Carcinoma on Top of Liver Cirrhosis

NCT04763707

Hepatocellular Carcinoma

COMPLETED

Predictors of HCC in Post-HCV Cirrhotic Patients After SVR

NCT07097870

HCC - Hepatocellular Carcinoma

NOT_YET_RECRUITING

Early Screening of Hepatocellular Carcinoma in Cirrhotic Patients: a Prospective Study

NCT00629421

Cirrhosis Hepatocellular Carcinoma

COMPLETED

The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt

NCT05047146

Hepatocellular Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cases group

cirrhotic patients with early hepatocellular carcinoma

measure of Glutamine synthetase and BCLFAF1

Intervention Type OTHER

compare Glutamine synthetase and BCLFAF1 in cases and controls

control group

cirrhotic patients with no hepatocellular carcinoma

measure of Glutamine synthetase and BCLFAF1

Intervention Type OTHER

compare Glutamine synthetase and BCLFAF1 in cases and controls

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

measure of Glutamine synthetase and BCLFAF1

compare Glutamine synthetase and BCLFAF1 in cases and controls

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A total 90 adult patients with liver cirrhosis attending the outpatient clinic or in patient section of the department of tropical medicine and gastroenterology at Sohag University Hospital will be included in the study. Patients will be divided into two groups:

Group I:

The study group will include 45 patients diagnosed with liver cirrhosis with absence of hepatic focal lesion as control group. Cirrhosis will be determined according to clinical , sereological ,radiological findings.

Group II:

The study group will include 45 patient with HCC on top of liver cirrhosis .All causes of liver cirrhosis will be accepted .HCC will be assessed by triphasic CT or MRI or histological validation .In these group we will take patients with liver cirrhosis with early hepatocellular carcinoma that defined as tumors smaller than 3cm and three or fewer in number at stage A according to BCLC staging also sometimes it includes solitary tumors up to 5 cm in size as defined in the Milan criteria. Both very early and early stage tumors are relatively small but both are hyper vascular in arterial phase.

Exclusion Criteria

1. Non cirrhotic patients.
2. Patients with distant metastasis.
3. Patients aged below18 years.
4. Patients with other malignancy rather than HCC.
5. Patients with late stage of HCC.

Eligible Sex

ALL

Accepts Healthy Volunteers

No